PDMR Dealing

RNS Number : 5604R
Oxford BioDynamics PLC
30 June 2020
 

30 June 2020

 

Oxford BioDynamics Plc

( "OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

PDMR Dealing

 

Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that Peter Pack, Non-Executive Chairman, has purchased 15,000 ordinary shares of 1 pence each ("Ordinary Shares") at an average price of 62.00p* per Ordinary Share.

 

Following this transaction, Peter Pack is interested in 15,000 Ordinary Shares, representing 0.02% of the Company's current issued share capital.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Peter Pack

2

Reason for the notification

a)

Position/status 

Non-Executive Chairman

b)

Initial notification/ Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oxford BioDynamics Plc 

b)

LEI

2138005Y1TK258O5U928

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary Shares of 1 pence each

 

ISIN:  GB00BD5H8572

b)

Nature of the transaction

Acquisition of ordinary shares

c)

Price and volume

 

Price(s)

Volume(s)

0.6 2

1 5,000

 

 

d)

Aggregated information

- Aggregated volume

- Price

 

 

Price

Volume

0.6 2

1 5,000

 

 

e)

Date of the transaction

29 June 2020 

f)

Place of the transaction

Outside a trading venue (Börse Stuttgart)

 

* average price calculated using average GBP/EUR exchange rate on the date of the transaction of 1€ = £0.91383

 

 

For further details please contact:

 

Oxford BioDynamics Plc

Jon Burrows, CEO

Paul Stockdale, CFO

 

+44 (0)1865 518910

Shore Capital

Nominated Adviser and Broker

Stephane Auton

Edward Mansfield

John More

 

+44 (0)20 7408 4090

FTI Consulting

Financial Public Relations Adviser

Natalie Garland-Collins

 

+44 (0)20 3727 1000

 

Notes for Editors

 

About Oxford BioDynamics Plc

 

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry. 

 

The Company's award-winning, proprietary technology platform, EpiSwitch™, offers non-invasive liquid biopsy readouts to the standards of validated predictive, prognostic and diagnostic patient stratifications, and aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. 

 

In particular, EpiSwitch™ offers non-invasive molecular read-outs with strong links to clinical outcomes, and helps reduce time to market, failure rates and the costs at every stage of drug discovery.  Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

 

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

 

The Company is headquartered in the UK and listed on the London Stock Exchange's AIM under the ticker "OBD".  For more information please visit  www.oxfordbiodynamics.com .

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFMMTTMTMJBJM
UK 100

Latest directors dealings